Journal
RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY
Volume 5, Issue 3, Pages 172-187Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/157489210791760526
Keywords
Anti-cancer drug; alkylating drug; DNA damage; temozolomide; triazenes
Categories
Funding
- Ministero Italiano dell'Universita e della Ricerca
- RSA Tor Vergata
Ask authors/readers for more resources
Temozolomide (TMZ) is a monofunctional methylating agent which is spontaneously activated in aqueous solution into the dacarbazine metabolite 5-(3-methyl-1-triazeno)imidazole-4-carboxamide. This drug has been approved for the treatment of metastatic melanoma and glioblastoma multiforme, the latter in combination with radiotherapy. Furthermore, clinical trials have been performed to assess the activity of TMZ, alone or in combination, on brain metastatic solid tumors and leukaemias. This review will report clinical evidence on the use of TMZ for the treatment of different types of cancer; it also considers current knowledge on TMZ's molecular mechanisms of action of and discusses relevant patents relating to the same drug.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available